中华肿瘤杂志最新文献

{"title":"[Expert consensus on the treatment of advanced lung cancer in elderly patients (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112152-20250326-00128","DOIUrl":"10.3760/cma.j.cn112152-20250326-00128","url":null,"abstract":"<p><p>Lung cancer exhibits the highest incidence and mortality among all malignancies in China, with incidence peaking after age 65. The growing elderly population has led to a significant increase in both the number and proportion of elderly lung cancer patients, necessitating standardized management for this group. The \"Consensus of Chinese experts on medical treatment of advanced lung cancer in the elderly (2022 edition)\" has provided essential clinical guidance in the past 2 years. However, evolving evidence-based medical findings and pharmaceutical advancements necessitate consensus updates. Against this backdrop, the Expert Committee on Geriatric Oncology Prevention and Treatment of the Chinese Society of Clinical Oncology (CSCO) has developed the \"Expert consensus on the treatment of advanced lung cancer in elderly patients (2025 edition). Based on the 2022 edition, this revision encompasses five key domains: definition and characteristics of the elderly population, comprehensive geriatric assessment for elderly advanced lung cancer patients, treatment of advanced non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC) in elderly patients, and management of treatment-related adverse events. The core features of this consensus update are highlighted as follows: 1. Refined age-stratified management. Patients are categorized into three strata: younger-old (65-74 years), middle-old (75-84 years), and oldest-old (≥85 years), with precision management emphasized for each stratum. 2. Elevated role of comprehensive geriatric assessment. Positioning comprehensive geriatric assessment as an essential core tool throughout diagnosis and treatment. 3. Stratified precision treatment strategies. Treatment selection for NSCLC/ES-SCLC patients should balance efficacy and quality of life based on age stratification and comprehensive geriatric assessment. 4. Enhanced focus on drug safety and interactions. Prioritizing drug-drug interactions (DDIs) alongside safer drug selection and adverse event monitoring. Nine key recommendations were finalized to guide clinical practice, promoting rational and standardized management of advanced lung cancer in elderly patients in China.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 ","pages":"575-598"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[MiR-1-3p inhibits mitophagy in esophageal squamous cell carcinoma by targeting SLC7A11].","authors":"S M Zhen, H R Zhang, J X Si, J Q Wang, Y Zhao, Y L Jia, L H Liu","doi":"10.3760/cma.j.cn112152-20240219-00078","DOIUrl":"https://doi.org/10.3760/cma.j.cn112152-20240219-00078","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the effect of miR-1-3p on mitophagy in human esophageal squamous cell carcinoma (ESCC) cells and the related mechanisms. &lt;b&gt;Methods:&lt;/b&gt; The differentially expressed miRNAs in ESCC were screened using the GEO database. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to measure miR-1-3p expression in normal esophageal epithelial cells (HET-1A) and ESCC cell lines (TE1, KYSE30, KYSE150, KYSE410, Eca109). Bioinformatics tools were utilized to predict target genes of miR-1-3p, subcellular localization was confirmed by fluorescence in situ hybridization. The targeting relationship between miR-1-3p and SLC7A11 was validated using dual-luciferase reporter assay. Cell proliferation and apoptosis were detected by CCK8 assay and flow cytometry, respectively. Furthermore, experimental validation demonstrated that overexpression of SLC7A11 rescued the presence of the miR-1-3p/SLC7A11 axis. Confocal microscopy was used to detect changes in mitochondrial autophagic lysosomes, while transmission electron microscopy was employed to observe mitophagy and morphological alterations. Western blot was conducted to evaluate the expression of autophagy-related proteins LC3 and P62. Flow cytometry was used to measure mitochondrial membrane potential and reactive oxygen species (ROS). Immunohistochemistry was applied to assess SLC7A11 expression in 133 ESCC patient tissues and 115 normal esophageal epithelial tissues. The correlation between SLC7A11 expression level and clinicopathological features was analyzed. Survival analysis was performed using the Kaplan-Meier method, and Cox proportional hazard regression models were used for multivariate analysis. &lt;b&gt;Results:&lt;/b&gt; The expression of miR-1-3p in ESCC cells was significantly lower than that in HET-1A cells (&lt;i&gt;P&lt;/i&gt;＜0.05). SLC7A11 was a target gene of miR-1-3p. Transfection of miR-1-3p mimic inhibited the proliferation of ESCC cells. CCK-8 assay results showed that the proliferative capacity of KYSE30 and KYSE410 cells in the miR-1-3p mimic group (absorbance values: 2.88±0.24 and 2.88±0.18, respectively) was significantly lower than that in the miRNA mimic negative control (NC) group (3.94±0.27, &lt;i&gt;P&lt;/i&gt;＜0.001; 4.20±0.21, &lt;i&gt;P&lt;/i&gt;＜0.001). Meanwhile, the proliferative capacity of KYSE30 and KYSE410 cells in the miR-1-3p mimic+SLC7A11-overexpression (OE) group (absorbance values: 3.57±0.15 and 3.60±0.13, respectively) was significantly higher than that in the miR-1-3p mimic +empty vector (EV) group (2.54±0.10, &lt;i&gt;P&lt;/i&gt;＜0.001, 2.36±0.16, &lt;i&gt;P&lt;/i&gt;＜0.001). Additionally, transfection of miR-1-3p mimic promoted apoptosis. Flow cytometry results demonstrated that the apoptosis rates of KYSE30 and KYSE410 cells in the miR-1-3p mimic group [(9.22±0.05)% and (6.55±0.37)%, respectively] were significantly higher than those in the miRNA mimic NC group [(0.81±0.17)%,&lt;i&gt;P&lt;/i&gt;＜0.001); (1.04±0.12)%, &lt;i&gt;P&lt;/i&gt;＜0.001]. Conversely, the apoptosis rates of KYSE30 and KYSE410 cells ","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"645-656"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical expert consensus on the application of long-acting granulocyte colony-stimulating factor in gynecologic malignancies (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112152-20241105-00477","DOIUrl":"10.3760/cma.j.cn112152-20241105-00477","url":null,"abstract":"<p><p>Ovarian cancer, cervical cancer, and endometrial cancer are the three major malignant tumors in gynecologic oncology, with an increasing incidence rate in recent years. Chemotherapy, radiotherapy, immunotherapy, and targeted therapy remain the mainstays of treatment; however, all may cause varying degrees of myelosuppression, with neutropenia being the most common adverse effect. Notably, the incidence of grade ≥3 neutropenia among gynecologic oncology patients undergoing antitumor therapy is significantly higher than that in patients with other solid tumors, leading to increased risk of severe infections, prolonged hospitalization, and potentially life-threatening complications. Therefore, effective prevention and management of neutropenia are crucial to ensuring treatment adherence and maintaining patients' quality of life. A growing body of evidence has demonstrated the clinical value of long-acting granulocyte colony-stimulating factor (G-CSF) in the prevention and management of neutropenia. Based on the latest evidence in evidence-based medicine, this expert consensus provides an overview of neutropenia commonly encountered during chemoradiotherapy in patients with gynecologic malignancies and highlights its potential impact on treatment outcomes. It then systematically introduces the long-acting G-CSF currently approved by the U.S. Food and Drug Administration (FDA) and Chinese regulatory authorities. The consensus further elaborates on the clinical applications of long-acting G-CSF in the prevention of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN), and presents corresponding recommendations. Additionally, it outlines the differentiated use of long-acting G-CSF in primary and secondary prophylaxis, along with recommended dosing regimens and administration strategies based on recent literature. Potential adverse effects and corresponding management strategies of long-acting G-CSF are also systematically reviewed. To promote the standardized use of long-acting G-CSF in gynecologic cancer treatment, this 2025 edition of the expert consensus has been jointly developed by leading domestic experts, providing comprehensive guidance and evidence-based recommendations for rational clinical use in this field.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"635-644"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Consensus on recurrence risk and clinical management of HR+/HER-2- early breast cancer (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112152-20250524-00240","DOIUrl":"https://doi.org/10.3760/cma.j.cn112152-20250524-00240","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Breast cancer is the most common malignancy among women worldwide, with relatively high morbidity and mortality rates among Chinese women, posing a serious threat to female health. HR+/HER-2- breast cancer is the most common subtype, accounting for approximately 70% of all breast cancers. The vast majority of patients are diagnosed with early breast cancer (EBC) at initial presentation. Stage Ⅱ-Ⅲ EBC constitutes a substantial proportion of cases among Chinese patients, with a significantly younger age of onset observed nationally. Even after standard endocrine therapy, patients still face short-term and long-term recurrence risks, and the risk of recurrence persists lifelong. In recent years, large-scale real-world studies from the National Cancer Center and other institutions, both domestically and internationally, have shown that for stage Ⅱ-Ⅲ HR+/HER-2- EBC patients, those with lymph node positivity and lymph node negative patients with high-risk factors have a significantly higher risk of recurrence and death. The postoperative 5-year recurrence rate for lymph node negative patients with high-risk factors can reach 15%, similar to the recurrence rate of N1 patients. These findings have updated the clinical understanding of defining high-risk patients and raised new requirements for EBC recurrence risk assessment and definition. On the other hand, the clinical management of recurrence risk in early HR+/HER-2- breast cancer has consistently received significant attention. From the initial adjuvant chemotherapy to the entire process of adjuvant endocrine therapy, in recent years, with the publication of clinical trial results for novel targeted agents such as CDK4/6 inhibitors (CDK4/6i) and PARP inhibitors (PARPi) and the subsequent approval of their indications, the treatment paradigm for HR+/HER-2- EBC has gradually evolved from traditional endocrine therapy to a selective strategy of intensified treatment combining endocrine therapy with targeted agents. This underscores the critical importance of precise recurrence risk assessment and optimization of treatment decisions. To assist clinicians in scientifically and accurately assessing recurrence risk and tailoring individualized intensified adjuvant treatment regimens for patients, the Breast Cancer Expert Committee of the National Cancer Quality Control Center, the Professional Committee of Drug Clinical Research of Chinese Anti-Cancer Association, and the Professional Committee of Breast Cancer of the Chinese Anti-Cancer Association, incorporating advances in clinical research on early breast cancer both domestically and internationally and expert opinions, have formulated the \"Consensus on Recurrence Risk and Clinical Management of HR+/HER-2- Early Breast Cancer(2025 edition)\". It aims to provide a standardized reference for recurrence risk stratification and clinical management of HR+/HER-2-EBC patients, further enhancing patient treatment benefits and quality of life, and maximizin","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"599-616"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Lorlatinib primary hospital patient health management expert consensus (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112152-20250111-00021","DOIUrl":"10.3760/cma.j.cn112152-20250111-00021","url":null,"abstract":"<p><p>Lorlatinib is a novel third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) used for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC) patients. This drug exhibits high affinity, effectively overcoming various resistance mutations, and can penetrate the blood-brain barrier, demonstrating significant efficacy against brain metastases. Lorlatinib exhibits generally manageable safety profiles. To improve patients' adherence and maximize patients survival outcome, physicians need pay attention to lorlatinib related adverse events such as hyperlipidemia, edema, and hypertension, necessitating dose adjustments and symptom management based on individual patient conditions. The Beijing Cancer Prevention and Treatment Research Association has organized relevant experts to formulate the \"Lorlatinib primary hospital patient health management expert consensus (2025 edition)\". This expert consensus provides standardized guidance on the use of lorlatinib for primary hospitals, including pharmacological characteristics, indications, dosage, high-level evidence-based medical research, adverse event management strategy and individualized treatment options. The consensus emphasizes the periodically monitor, identification, assessment, and management of adverse reactions, as well as the importance of long-term follow-up, aiming to maximize the clinical benefits of lorlatinib, ensure the therapeutic effectiveness, improve patients' quality of life and achieve long-term survival.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 ","pages":"443-455"},"PeriodicalIF":0.0,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Exploration of biomarkers for the efficacy of anti-PD-1 immunotherapy in patients with gastric cancer peritoneal metastasis].","authors":"Y T Wei, Y Wang, J Yang, H B Wang, X Y Zhou, Y F Pan, S J Ren, W Q Liu, B R Liu, J Wei","doi":"10.3760/cma.j.cn112152-20240826-00368","DOIUrl":"10.3760/cma.j.cn112152-20240826-00368","url":null,"abstract":"<p><p><b>Objective:</b> To explore the prognosis of patients with gastric cancer peritoneal metastasis (PM) receiving programmed cell death-1 (PD-1) antibody therapy, and investigate the biomarkers that affect the prognosis of anti-PD-1 therapy. <b>Methods:</b> This restrospecific study collected the clinic-pathological data of 56 patients with peritoneal metastasis of gastric cancer who received first-line treatment in the Nanjing Drum Town Hospital from March 2020 to September 2023, among which 41 had received anti-PD-1 immunotherapy and 15 hadn't. The relationship between overall survival (OS) and anti-PD-1 immunotherapy was evaluated by Kaplan-Meier analysis. The relationship between baseline peripheral blood indicators and treatment response of patients with anti-PD-1 treatment was analyzed using unpaired <i>t</i>-test. Subsequently, the Cox proportional risk regression model was used to explore the clinical prognostic factors that may affect anti-PD-1 immunotherapy by univariate and multivariate analysis. The clinical prognostic factors included baseline data and baseline peripheral blood indexes such as anti-PD-1 treatment lines, Eastern Cooperative Oncology Group performance status (ECOG PS), combined positive score (CPS), expression of human epidermal growth factor receptor 2 (Her-2), EBER status, pathological types, other metastatic lesions, ascites content before immunotherapy, with or without abdominal drainage during anti-PD-1 treatment, blood lipid indicators, inflammatory indicators, and tumor indicators. <b>Results:</b> Kaplan-Meier survival statistics showed similar OS (15.9 vs. 15.2 months, <i>P</i>=0.600) in patients with anti-PD-1 therapy compared to those without anti-PD-1 therapy. Patients with baseline high-density lipoprotein (HDL) ≥0.97 mmol/L (<i>n</i>=22) demonstrated a significantly longer median OS compared to those with HDL＜0.97 mmol/L (15.2 vs. 13.5 months; <i>P</i>=0.018). Similarly, the cohort with apolipoprotein A1 (ApoA1) levels ≥0.86 g/L (<i>n</i>=21) showed superior survival outcomes, with a median OS of 17.7 months versus 12.3 months in the ApoA1＜0.86 g/L group (<i>n</i>=20; <i>P</i>=0.006). In contrast, elevated baseline alpha-fetoprotein (AFP) levels (<i>n</i>=2) were associated with markedly reduced survival (median OS: 5.7 vs. 15.2 months in normal AFP group, <i>n</i>=37; <i>P</i>=0.005). Notably, elevated pretreatment ApoA1 levels correlated with enhanced immunotherapy response (<i>P</i>=0.017). Multivariate Cox regression analysis revealed that ApoA1 deficiency (≥0.86 g/L) independently predicted better OS following PD-1 antibody therapy (<i>HR=</i>0.35, 95% <i>CI:</i> 0.12-0.98, <i>P</i>=0.046) in gastric cancer patients with PM. <b>Conclusions:</b> In our study, it is first proposed that ApoA1 could be a significant predictor of the survival advantages of immunotherapy in gastric cancer patients with PM.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 ","pages":"525-532"},"PeriodicalIF":0.0,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Rethinking cancer].","authors":"W R Luo","doi":"10.3760/cma.j.cn112152-20250401-00145","DOIUrl":"10.3760/cma.j.cn112152-20250401-00145","url":null,"abstract":"<p><p>Over the past half-century of the global effort against cancer, the vast majority of investigations in both tumor basic research and clinical practice have centered on the \"somatic mutation\" theory, such as in molecular classification, individualized precision medicine strategies, gene therapy approaches, the development of neoantigen-based tumor vaccines, and advancements in sequencing technologies. Even in the extensively studied tumor microenvironment (including tumor immunity), which has garnered significant attention in recent years, the underlying mechanisms frequently revert to specific genes and mutations within tumor cells or microenvironmental cells as the primary driving forces. However, despite the dominance of the \"somatic mutation\" paradigm, truly effective approaches for curing cancer in clinical settings remain elusive. Undoubtedly, if the prevailing \"somatic mutation theory\" continues to monopolize cancer research, meaningful progress in understanding and treating cancer will likely remain frustratingly out of reach. At this critical juncture in the evolution of cancer research, a comprehensive re-evaluation of cancer not only is necessary but also imperative, highlighting the urgent need for a profound transformation in our conceptual framework. This article systematically elucidates the novel perspective offered by the \"tumor system\" for comprehending the essence of cancer, the foundational principles of \"tumor ecology\" and their potential applications in treatment, and explores in depth the theoretical framework and research significance of the emerging field of \"ecological pathology\". Beyond merely advocating for the abandonment of the currently dominant linear reductionist paradigm of cancer, this commentary strives to construct a pragmatic and systematically structured framework to guide the trajectory of the \"post-genomic revolution in oncology\" and the \"tumor ecological philosophy\", ultimately fostering the realization of the overarching societal goal of eradicating cancer.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 ","pages":"463-467"},"PeriodicalIF":0.0,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress of tumor neoantigen-specific adoptive cellular immunotherapy].","authors":"Y M Wang, B R Liu, Q Liu","doi":"10.3760/cma.j.cn112152-20240924-00412","DOIUrl":"https://doi.org/10.3760/cma.j.cn112152-20240924-00412","url":null,"abstract":"<p><p>Tumour neoantigen sprimarily refer to a specific group of tumour antigens derived from tumour mutant proteins, but also including antigens generated by the oncogenic viruses integrated into the genome, which are not expressed by normal cells in the human body but are specifically expressed in tumor cells, and are capable of triggering the tumour-specific cellular and humoral immunity in the host. In recent years, significant advances in tumor immunotherapy such as therapeutic oncology vaccines, and adoptive cell therapy (ACT) have been acquired. However, standalone tumor therapeutic vaccines exhibit several drawbacks. They possess low immunogenicity, face a substantial tumor burden, and are highly susceptible to the immunosuppressive microenvironment. Consequently, when applied in isolation during clinical practice, their therapeutic efficacy remains limited. Compared with immunotherapies such as immune checkpoint inhibitors and tumor vaccines, ACT is less affected by the immunosuppressive microenvironment in the body and can generate a sufficient number of killer cells. The crux of ACT lies in the generation of immunogenic tumor-specific killer cells. Neoantigens enhance the immunogenicity and anti-tumor specificity of ACT. Among them, the ACT targeting mutant gene mutations, including <i>ERBB2IP</i>, <i>KRAS</i> and <i>TP53</i>, as well as those derived from viruses such as Epstein-Barr virus (EBV) and human papillomavirus (HPV), is primarily summarized. Moreover, the existing issues of neoantigen-specific ACT and corresponding countermeasures are summarized and discussed.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 4","pages":"298-307"},"PeriodicalIF":0.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Cancer burden in Hebei Province from 2011 to 2020].","authors":"D J Li, D Liang, J Shi, Y Y Liu, J Jin, B E Shan, Y T He","doi":"10.3760/cma.j.cn112152-20240110-00017","DOIUrl":"https://doi.org/10.3760/cma.j.cn112152-20240110-00017","url":null,"abstract":"<p><p><b>Objective:</b> To understand the burden of cancer disease in Hebei Province in recent years and to analyze the change trend of cancer in Hebei Province from 2011 to 2020. <b>Methods:</b> The incidence and death data of cancer were collected from 38 cancer registries in Hebei Province during 2011-2020. The incidence (mortality) rate, standardized incidence (mortality) rate and composition ratio of each region, sex, and age were calculated respectively, and the incidence and death of major cancers in our province were summarized. The age-standardized morbidity (mortality) rates of China and the world population were calculated using the 2000 China standard population composition and Segi's world population composition respectively. Trend analysis of morbidity and mortality was performed and average annual percentage change (AAPC) was calculated. <b>Results:</b> In 2020, the crude cancer incidence rate and the age-standardized morbidity rate of China was 229.36/100 000 and 147.06/100 000, respectively. An estimated 171 600 new cases were reported in the province. The crude cancer mortality rate and the age-standardized mortality rates of China was 146.38/100 000 and 85.33/100 000. The estimated number of deaths in the province is 108 900. In the cancer registration areas of Hebei Province, 84% of all cancer patients occurred in people 50 years of age and older. From 2011 to 2020, the incidence and mortality of cancer in Hebei Province showed a decreasing trend. The AAPC was -4.2% (<i>P</i>＜0.001), which decreased from 206.61/100 000 in 2011 to 143.74/100 000 in 2020. The world standard mortality rate of cancer was 147.69/100 000 in 2011, and decreased to 84.79/100 000 in 2020. The AAPC was -5.7% (<i>P</i>＜0.001). The world-standard incidence and mortality of lung cancer, esophageal cancer, gastric cancer, liver cancer and colorectal cancer decreased from 2011 to 2020. The AAPCs of the world-standard incidence were -4.0%, -12.3%, -9.4%, -6.0% and -1.6%, respectively. The AAPCs of the world-standard mortality were -4.9%, -11.3%, -8.5%, -5.7% and -3.3%, which were statistically significant. The incidence of thyroid cancer increased rapidly, the AAPC of which was 9.7% (<i>P</i>＜0.001). The rates of female breast cancer and male prostate cancer in Hebei Province were stable. <b>Conclusions:</b> The world-standard incidence and mortality of cancer in Hebei Provincial cancer registries areas show a downward trend from 2011 to 2020. However, the cancer incidence and mortality in Hebei Province are still at high levels. It's necessary to strengthen cancer prevention and control in Hebei Province, improve the awareness of cancer prevention and control in the whole society, and promote the concept of tertiary cancer prevention to reduce the cancer burden in Hebei Province.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 4","pages":"316-321"},"PeriodicalIF":0.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144064898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinicopathologic features with pulmonary and tracheal glomus tumor: report of 8 cases].","authors":"J X Zhou, P Ma, M L Bao, J L Tang, Z G Zou, H X Li","doi":"10.3760/cma.j.cn112152-20240827-00369","DOIUrl":"https://doi.org/10.3760/cma.j.cn112152-20240827-00369","url":null,"abstract":"<p><p><b>Objective:</b> To study the clinical and pathological features, immunophenotypes, molecular genetics characteristics, differential diagnosis, and prognostic factors of pulmonary and tracheal glomus tumors. <b>Method:</b> Eight cases of pulmonary and tracheal glomus tumors were collected in Jiangsu Provincial Hospital (including 1 consultation, from Gaochun People's Hospital, Nanjing, China) between May 2015 and April 2023, and their clinical and imaging data, pathological morphology, and immunohistochemical characteristics were retrospectively analyzed. Gene testing and follow-up were performed. <b>Result:</b> There were 5 males and 3 females with onset ages ranging from 29 to 75 years old, median age 63.5 years. Among the patients, 5 cases were located in the trachea and 3 cases in the lungs. Under light microscopy, 5 cases were benign glomus tumors with clear boundaries, diffuse sheet or nest-like distribution, small, round or short spindle-shaped tumor cells, rounded and centered nuclei, and no obvious nuclear mitosis was seen. Two cases of glomus tumor of uncertain malignant potential showed an infiltrative growth pattern involving smooth muscle, nerves and blood vessels with necrosis and calcification, the tumor cells were more uniform in size, round or short spindle-shaped nuclei, and no obvious nuclear mitosis was seen; One case of malignant glomus tumor was seen in sarcomatous areas, lung membrane invasion and necrosis, the tumor cells were highly heterogeneous, binucleated and multinucleated, with nuclear mitoses of 20/50 high power field (HPF), and pathologic nuclear mitoses were easy to be seen. Immunohistochemically, SMA, Calponin, H-caldesmon, Vimentin and Collagen Ⅳ were all positive (8/8). Some cases expressed Syn (3/8) and Bcl-2 (4/8). The Ki-67 proliferation index was 1-2% (7/8) and 40% (1/8). BRAF V600E were detected as wild-type (8/8), and no mutations were detected in exons 2, 3, and 4 of <i>KRAS</i> human <i>EML4</i>-<i>ALK</i> fusion gene were negative in 5 surgical cases. Case 6 showed <i>HMBOX1</i>-<i>ALK</i> gene fusion, <i>TERT</i> gene mutation and <i>CDKN2A</i> gene deletion, and case 8 showed <i>CARMN</i>-<i>NOTCH2</i> gene fusion. Seven cases were followed up (8-103 months, median follow-up time 30 months), 1 case was lost, 1 case recurred 21 months after surgery, and others with no evidence of recurrence or metastasis. <b>Conclusions:</b> Pulmonary and tracheal glomus tumors are very rare and need to be differentiated from other common tumors by combining pathological morphology and immunohistochemistry. Maybe there are some differences in the malignant diagnostic criteria and molecular genetic characteristics between visceral derived glomus tumors and soft tissue derived tumors of the same kind, such as limbs and skin. More data accumulation is needed.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 4","pages":"349-355"},"PeriodicalIF":0.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}